NEW YORK (AVAFIN) -- Block trades offer useful, insightful data used by both large and small investors to
determine if their stock trade will be profitable. By the end of today's trading
session, financial institutions exchanged 37 block trades. A total of
1,029,161 shares were bought and 845,595 shares were sold
forming a bought/sold ratio of 1.22 for Amylin Pharmaceuticals.
View all Block Trading Activities
On the options front, a total of 38,783 contracts were traded. Specifically, 31,176
call and 7,607 put contracts were traded yielding a 0.24 put/call ratio.
The last trading session witnessed a low of $25.01 and high of $26.25 during the day. Shares of Amylin Pharmaceuticals
gained $3.14 (+13.70%) to $26.06. The current trading volume of 12M is greater
than average volume of 5M shares. The stock's 52 week low is $8.03 and 52 week high is $25.84. Within the last week, the shares have gained 12.23% of their value.
Amylin is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes and obesity. The firm has two first-in-class medicines for diabetes, Symlin and Byetta. Byetta was developed in partnership with Eli Lilly, but the firms terminated their collaboration this year. Amylin's lead portfolio drug is a once-weekly version of Byetta called Bydureon, which has now been approved in Europe and the United States.